emavusertib,trastuzumab
curis
['trastuzumab', 'ca-4948', 'esophageal', 'gastric']
haeseong park, md, mph, presents the phase i trial of ca-4948, an irak4 inhibitor, in combination with folfox/pd-1 inhibitor +/- trastuzumab for untreated unresectable gastric and esophageal cancer poster (#141) at 8:00am in mccormick, hall a. #asco22 
A National Cancer Institute Comprehensive Cancer Center and member of the National Comprehensive Cancer Network